Monthly summary - January 2023

MONTHLY SUMMARY

What a difference a month makes! While December posted a large drawdown in stock prices, January saw one of the strongest starts of a year ever. The widespread pessimism and hence relatively low equity exposures at the end of 2022 quickly changed into a risk-on sentiment, much to the chagrin of many large investment banks who had predicted further downward movements. This was not least seen in the losers of 2022. US technology companies and other high-multiple names, for instance, saw their stock prices soar in January, leading to an increase in the Nasdaq index of more than 10 percent.

Q4 earnings held up well 

Another positive ingredient to the investment community’s increased risk appetite was the start of the Q4 reporting season. Even though many companies had communicated uncertain outlooks for 2023, earnings held up well, again contradicting the doomsday view that permeated last year.

Central banks stayed in focus 

As has been the case for more than a year, investors’ focus remained firmly on central banks’ rate decisions. Following a period of fear that steep hikes would continue for an extended period, the general view changed slightly in January to a belief that many central banks would successively dampen the increases and then await the effects of a stricter monetary policy.

Warm winter winds in Europe 

Another (unusual) development that influenced investors positively was the weather in Europe. The much warmer than usual winter mitigated the disrupted flows of energy from Russia. Natural gas prices fell below pre-war levels, helping economic activity in the region. Subsequently, European equity markets outperformed the broader US markets as the negative effects of the war in Ukraine seemed to be less severe than expected going into 2023.

Increased support to Ukraine, and negotiations deemed far away

As far as the war in Ukraine was concerned, the stakes seemed to have been upped. Russia was observed to be amassing additional forces, presumably as preparations for a renewed offensive later this winter or early in the spring. The western powers, led by the US, pledged additional support, ranging from tanks to long distance missiles. The prospects of any negotiations were deemed to be more distant than ever.

Other news struggled to make headlines 

Apart from interest rates, earnings and the war, little else made headlines. The difficult process to appoint Kevin McCarthy as the speaker of the US House of Representatives following resistance from other Republican congressmen, was largely ignored by investors. Also, the looming debt ceiling faded into the background. The European Commission proposed wide-ranging subsidies to various industrial sectors in a response to the Biden administration’s IRA (Inflation Reduction Act), which could be seen as hampering global trade.

Remarkable comeback in January

Following a very tough year for equity investors, the world index made a remarkable comeback in January. With the exception of healthcare, which saw a marginal retreat, all global sectors advanced led by information technology and consumer discretionary. Geographically, all major stock markets rose with the Nasdaq and Hong Kong at the forefront, while Japan and the broader S&P500 trailed the MSCI world index.

 

OUTLOOK

The strong development in the world’s financial markets surprised many. With the benefit of hindsight, it is easy to find explanations. The earnings season began with relatively few profit warnings and many companies announced better than expected results. Stock sales due to tax considerations are common in many markets, and after a weak year, many such sales tend to take place in December and then decline significantly. This was the case this time around. After a sharp decline in the stock market, many growth stocks have now come down to levels that many long-term investors perceive as more reasonable. Once the market then stabilizes and rises, hedge funds will also be back in and cover short positions in order not to take excessive risks of ending up wrong-footed relative to the market, not least critically at the beginning of a new year.

The beginning of the end of interest rates hikes?

Most importantly, markets are now seeing the beginning of the end of interest rate hikes by the Fed, which historically tends to be a period of decent stock market developments. Inflation in the US is coming down significantly from very high levels and is expected to continue down markedly during the first half of the year. At the same time, the Chicago Fed’s measure of Financial Conditions (a measure of how favorable the climate is for financial assets) has improved for the stock market since last fall. In short, the conditions for the financial markets have become more generous, and accordingly asset prices are rising.

The sector may lag in this environment

The healthcare sector tends to lag in this type of market and may do so for some timeWe are hopeful of a stronger year this year if inflation continues to decline and then stabilize. Inflation is crucial. The lower the inflation, the lower the interest rates, and thus better are the conditions for growth companies.

The earnings season for the sector has just begun. Nothing indicates that it is weak, quite the opposite in fact. However, several companies are still suffering from tough comparisons due to Covid sales or the fact that the labor market has not yet succeeded in re-employing important specialists in healthcare. We are hopeful that this will happen. The longer the year goes on, the better the conditions for our sector will be. Other parts of the stock market may nevertheless have better outlooks when the economy’s wheel begins to spin and inflation gradually subsides. We believe the long-term prospects for growth in the healthcare sector are still good.

More articles

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

EN